1. Home
  2. NSPR vs IFRX Comparison

NSPR vs IFRX Comparison

Compare NSPR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$1.59

Market Cap

81.8M

Sector

Health Care

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.02

Market Cap

81.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSPR
IFRX
Founded
2005
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.8M
81.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
NSPR
IFRX
Price
$1.59
$1.02
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$4.00
$8.50
AVG Volume (30 Days)
48.1K
656.0K
Earning Date
11-04-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,779,000.00
$73,729.00
Revenue This Year
$22.76
N/A
Revenue Next Year
$75.45
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
14.04
N/A
52 Week Low
$1.58
$0.71
52 Week High
$3.80
$2.77

Technical Indicators

Market Signals
Indicator
NSPR
IFRX
Relative Strength Index (RSI) 33.92 43.09
Support Level $1.78 $0.99
Resistance Level $1.95 $1.16
Average True Range (ATR) 0.16 0.08
MACD -0.03 0.00
Stochastic Oscillator 12.12 13.04

Price Performance

Historical Comparison
NSPR
IFRX

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: